Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 7/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8903050 | 1.00 | PRKCA (0.41) | PRKCAGBA1SPHK2SPHK1 | |
| SCHEMBL51075 | 1.00 | PRKCA (0.41) | PRKCAGBA1SPHK2SPHK1 | |
| SCHEMBL8903045 | 1.00 | PRKCA (0.41) | PRKCAGBA1SPHK2SPHK1 | |
| SCHEMBL8990176 | 0.98 | PRKCA (0.44) | PRKCAGBA1SPHK2SPHK1 | |
| SCHEMBL7344383 | 0.98 | PRKCA (0.44) | PRKCAGBA1SPHK2SPHK1 | |
| SCHEMBL8915089 | 0.98 | PRKCA (0.44) | PRKCAGBA1SPHK2SPHK1 | |
| SCHEMBL4980804 | 0.98 | PRKCA (0.44) | PRKCAGBA1SPHK2SPHK1 | |
| SCHEMBL7344379 | 0.98 | PRKCA (0.44) | PRKCAGBA1SPHK2SPHK1 | |
| SCHEMBL7348308 | 0.98 | PRKCA (0.44) | PRKCAGBA1SPHK2SPHK1 | |
| SCHEMBL7343605 | 0.98 | PRKCA (0.44) | PRKCAGBA1SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2016-11-10 | — | — | US | disclosed |
| US-9272991-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | PRKCA 444/4885GBA1 3317/4885SPHK2 563/4885 |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | PRKCA 399/4885GBA1 3491/4885SPHK2 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.